Compass Pathways Plc - ADR Stock
$2.65
6.36%
today
Nasdaq,
Apr 04, 09:18 pm CET
Compass Pathways Plc - ADR Stock price
$2.83
-0.84
22.89%
1M
-3.06
51.95%
6M
-0.95
25.13%
YTD
-6.87
70.82%
1Y
-11.35
80.04%
3Y
-14.17
83.35%
5Y
-14.17
83.35%
10Y
Nasdaq,
Closing price Thu, Apr 03 2025
-0.26
8.41%
Powered by
Key metrics
| Market capitalization | $194.00m |
| Enterprise Value | $60.72m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 1.25 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-178.27m |
| Free Cash Flow (TTM) Free Cash Flow | $-119.24m |
| Cash position | $165.47m |
Show more
Is Compass Pathways Plc - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
Compass Pathways Plc - ADR Stock Analysis
Unlock Scores for Free
Analyst Opinions
12 Analysts have issued a Compass Pathways Plc - ADR forecast:
Analyst Opinions
12 Analysts have issued a Compass Pathways Plc - ADR forecast:
Buy
100%
Financial data from Compass Pathways Plc - ADR
| Dec '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.23 -0.23 |
-
|
|
| EBITDA | -178 -178 |
30%
30%
|
EBIT (Operating Income) EBIT | -178 -178 |
30%
30%
|
| Net Profit | -155 -155 |
31%
31%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Compass Pathways Plc - ADR directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Compass Pathways Plc - ADR Stock News
Neutral
GlobeNewsWire
●
7 days ago
This is a test from GlobeNewswire. Readers are advised to disregard.
Neutral
Business Wire
●
9 days ago
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the completion of recruitment in the COMP005 phase 3 trial for treatment resistant depression (TRD). The final participants are completing pre-dosing activities, including washout from anti-depr...
Neutral
Business Wire
●
17 days ago
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the publication of results from the COMP004 study, an observational 52-week follow-up from the Phase 2 COMP001 and COMP003 trials of COMP360 psilocybin treatment in patients with treatment-resis...
Company Profile
| Head office | United Kingdom |
| CEO | Kabir Nath |
| Employees | 166 |
| Founded | 2016 |
| Website | compasspathways.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
